Table of Content


List of Tables
List of Figures
Introduction
Global Markets Direct Report Coverage
RAF Proto Oncogene Serine/Threonine Protein Kise (Proto Oncogene c RAF or RAF1 or EC 2.7.11.1) - Overview
RAF Proto Oncogene Serine/Threonine Protein Kise (Proto Oncogene c RAF or RAF1 or EC 2.7.11.1) - Therapeutics Development
Products under Development by Stage of Development
Products under Development by Therapy Area
Products under Development by Indication
Products under Development by Companies
Products under Development by Universities/Institutes
RAF Proto Oncogene Serine/Threonine Protein Kise (Proto Oncogene c RAF or RAF1 or EC 2.7.11.1) - Therapeutics Assessment
Assessment by Mechanism of Action
Assessment by Route of Administration
Assessment by Molecule Type
RAF Proto Oncogene Serine/Threonine Protein Kise (Proto Oncogene c RAF or RAF1 or EC 2.7.11.1) - Companies Involved in Therapeutics Development
Apollomics Inc
Bayer AG
Chengdu Fanxi Biopharma Co Ltd
Deciphera Pharmaceuticals Inc
Hanmi Pharmaceuticals Co Ltd
Jazz Pharmaceuticals Plc
Metagone Biotech Inc
Novartis AG
Quanta Therapeutics Inc
Samjin Pharm Co Ltd
Siromics Ltd
SyntheX Inc
Takeda Pharmaceutical Co Ltd
Verastem Inc
RAF Proto Oncogene Serine/Threonine Protein Kise (Proto Oncogene c RAF or RAF1 or EC 2.7.11.1) - Drug Profiles
(MG-005 + sorafenib) - Drug Profile
Product Description
Mechanism Of Action
History of Events
(MG-010 + sorafenib) - Drug Profile
Product Description
Mechanism Of Action
History of Events
APL-102 - Drug Profile
Product Description
Mechanism Of Action
History of Events
avutometinib - Drug Profile
Product Description
Mechanism Of Action
History of Events
belvarafenib - Drug Profile
Product Description
Mechanism Of Action
History of Events
DCBCI-0902 - Drug Profile
Product Description
Mechanism Of Action
DCC-3084 - Drug Profile
Product Description
Mechanism Of Action
FNX-006 - Drug Profile
Product Description
Mechanism Of Action
History of Events
FYA-1001 - Drug Profile
Product Description
Mechanism Of Action
JZP-815 - Drug Profile
Product Description
Mechanism Of Action
History of Events
porafenibum - Drug Profile
Product Description
Mechanism Of Action
History of Events
regorafenib - Drug Profile
Product Description
Mechanism Of Action
History of Events
SJP-1601 - Drug Profile
Product Description
Mechanism Of Action
History of Events
SJP-601 - Drug Profile
Product Description
Mechanism Of Action
Small Molecule to Inhibit FLT, FLT3, FLT4, FMS, c-KIT, LYN, RAF1, RET, PDGFRa and PDGFRb for Oncology - Drug Profile
Product Description
Mechanism Of Action
Small Molecule to Inhibit Pan-RAF Kise for Oncology - Drug Profile
Product Description
Mechanism Of Action
History of Events
Small Molecules to Inhibit CRAF and BRAF for Oncology - Drug Profile
Product Description
Mechanism Of Action
Small Molecules to Inhibit RAF for Unspecified Cancer - Drug Profile
Product Description
Mechanism Of Action
Small Molecules to Inhibit RAF1 for Unspecified Cancer - Drug Profile
Product Description
Mechanism Of Action
STP-902 - Drug Profile
Product Description
Mechanism Of Action
STX-200 - Drug Profile
Product Description
Mechanism Of Action
tovorafenib - Drug Profile
Product Description
Mechanism Of Action
History of Events
RAF Proto Oncogene Serine/Threonine Protein Kise (Proto Oncogene c RAF or RAF1 or EC 2.7.11.1) - Dormant Products
RAF Proto Oncogene Serine/Threonine Protein Kise (Proto Oncogene c RAF or RAF1 or EC 2.7.11.1) - Discontinued Products
RAF Proto Oncogene Serine/Threonine Protein Kise (Proto Oncogene c RAF or RAF1 or EC 2.7.11.1) - Product Development Milestones
Featured News & Press Releases
Nov 11, 2022: Day One announces upcoming presentations at 2022 Society for Neuro-Oncology Annual Meeting
Oct 04, 2022: Verastem Oncology announces RAMP VS-6766 clinical trials and corporate updates
Sep 21, 2022: Global Coalition for Adaptive Research announces that Regorafenib has completed follow-up in the Gbm Agile trial for patients with glioblastoma
Jun 15, 2022: FDA grants IND clearance for Jazz and Redx’s cancer drug application
Jun 12, 2022: Day One announces positive initial data from pivotal FIREFLY-1 trial of tovorafenib (DAY101) in relapsed pediatric low-grade glioma
Jun 06, 2022: Verastem Oncology provides update on RAMP 201 study evaluating VS-6766 defactinib in low-grade serous ovarian cancer
May 23, 2022: Day One announces first patients dosed in phase 1b/2 combition study with tovorafenib (DAY101) and pimasertib in RAF-altered solid tumors
May 18, 2022: Verastem Oncology awarded Pancreatic Cancer Action Network’s first therapeutic Accelerator Award to evaluate the combition of VS-6766 and Defactinib in front-line metastatic pancreatic cancer
Apr 08, 2022: Jazz Pharmaceuticals presents pre-clinical data for pan-RAF inhibitor JZP815, including pharmacokinetic properties and efficacy in multiple solid tumor types
Mar 28, 2022: Verastem Oncology provides fincial update to support development of VS-6766 and defactinib in RAS pathway-driven tumors
Mar 08, 2022: Jazz Pharmaceuticals to present Pan-RAF inhibitor pre-clinical data at American Association for Cancer Research (AACR) 2022 Annual Meeting
Nov 22, 2021: Day One announces first patient dosed in phase 2 monotherapy study in RAF-altered solid tumors
Nov 03, 2021: Day One announces presentation at 2021 Connective Tissue Oncology Society (CTOS) Virtual Annual Meeting
Sep 19, 2021: ICR says drug combo demonstrates effectiveness in ovarian cancer trial
Sep 09, 2021: Bayer to present abstracts on Stivarga (regorafenib)at ESMO Congress 2021
Appendix
Methodology
Coverage
Secondary Research
Primary Research
Expert Panel Validation
Contact Us
Disclaimer



List of Figures

List of Figures
Number of Products under Development by Stage of Development, 2022
Number of Products under Development by Therapy Areas, 2022
Number of Products under Development by Top 10 Indications, 2022
Number of Products by Mechanism of Actions, 2022
Number of Products by Stage and Mechanism of Actions, 2022
Number of Products by Top 10 Routes of Administration, 2022
Number of Products by Stage and Top 10 Routes of Administration, 2022
Number of Products by Top 10 Molecule Types, 2022
Number of Products by Stage and Top 10 Molecule Types, 2022

List of Tables

List of Tables
Number of Products under Development by Stage of Development, 2022
Number of Products under Development by Therapy Areas, 2022
Number of Products under Development by Indications, 2022
Number of Products under Development by Companies, 2022
Products under Development by Companies, 2022
Number of Products under Investigation by Universities/Institutes, 2022
Products under Investigation by Universities/Institutes, 2022
Number of Products by Stage and Mechanism of Actions, 2022
Number of Products by Stage and Route of Administration, 2022
Number of Products by Stage and Molecule Type, 2022
Pipeline by Apollomics Inc, 2022
Pipeline by Bayer AG, 2022
Pipeline by Chengdu Fanxi Biopharma Co Ltd, 2022
Pipeline by Deciphera Pharmaceuticals Inc, 2022
Pipeline by Hanmi Pharmaceuticals Co Ltd, 2022
Pipeline by Jazz Pharmaceuticals Plc, 2022
Pipeline by Metagone Biotech Inc, 2022
Pipeline by Novartis AG, 2022
Pipeline by Quanta Therapeutics Inc, 2022
Pipeline by Samjin Pharm Co Ltd, 2022
Pipeline by Sirnaomics Ltd, 2022
Pipeline by SyntheX Inc, 2022
Pipeline by Takeda Pharmaceutical Co Ltd, 2022
Pipeline by Verastem Inc, 2022
Dormant Products, 2022
Dormant Products, 2022 (Contd..1)
Dormant Products, 2022 (Contd..2)
Discontinued Products, 2022